Alpha-Lipoic-Acid Cancer Research Results

ALA, Alpha-Lipoic-Acid: Click to Expand ⟱
Features: antioxidant, energy production in cell mitochondria
Alpha-Lipoic-Acid: also known as lipoic acid or thioctic acid (reduced form is dihydrolipoic acid).
"Universal antioxidant" because it is both water- and fat-soluble and can neutralize free radicals.
-Treatment sometimes as ALA/N (alpha-lipoic acid/low-dose naltresone)
-Also done in IV
-Decreases ROS production, but also has pro-oxidant role.
Normal adult can take 300 milligrams twice a day with food, but they should always take a B-complex vitamin with it. Because B complex vitamins, especially thiamine, and biotin, and riboflavin, are depleted during this metabolic process.
α-Lipoic acid acts as a chelating agent for metal ions, a quenching agent for reactive oxygen species, and a reducing agent for the oxidized form of glutathione and vitamins C and E.
-It seems a paradox that LA functions as both antioxidant and prooxidant. LA functions the pro-oxidant only in special cancer cells, such as A549 and PC9 cells which should show high-level NRF2 expression and high glycolytic level. Through inhibiting PDK1 to further prohibit NRF2; LA functions as anticancer prooxidant.

α-lipoic acid possesses excellent silver chelating properties.

ALA → ROS ↑ (cancer cells; high dose / stressed mitochondria)
ALA → ROS ↓ (normal cells; low–moderate dose)
same pattern seen with: Vitamin C, Menadione, Quercetin, EGCG, Resveratrol
- ALA acts as pro-Oxidant only in cancer cells:#278 - Pro-Oxidant Dose margin >100uM:#304

- Bioavailability: 80-90%, but conversion to EPA/DHA is 5-10% (and takes longer time).
- AI (Adequate Intake): 1.1-1.6g/day.
- human studies have shown that ALA levels decline significantly with age
- 1g of ALA might achieve 500uM in the blood.
- ALA is poorly soluble, lecithin has been used as an amphiphilic matrix to enhance its bioavailability.
- Pilot studies or observational interventions have used flaxseed supplementation (rich in ALA) in doses providing roughly 3–4 g of ALA daily.
- Flaxseed oil is even more concentrated in ALA – typical 50–60% ALA by weight.
- single walnut may contain 300mg of ALA
- chia oil contains 55-65% ALA.
- α-LA can also be obtained from the diet through the consumption of dark green leafy vegetables and meats
- ALA is more stable in chia seeds, (2grams of ALA per tablespoon)
- ALA degrades when exposed to heat, light, and air. (prone to oxidation)

-Note half-life 1-2 hrs.
BioAv 30-40% from walnuts, 60-80% from supplements. Co-ingestion with fat improves absorption. Both fat and water soluble
Pathways:
- induce ROS production
- ROS↑ related: MMP↓(ΔΨm), ER Stress↑, UPR↑, GRP78↑, Cyt‑c↑, Caspases↑, DNA damage↑,
- Lowers AntiOxidant defense in Cancer Cells: NRF2↓, SOD↓, GSH↓ Catalase↓ HO1↓ GPx↓
- Raises AntiOxidant defense in Normal Cells: ROS↓, NRF2↑, SOD↑, GSH↑, Catalase↑,
- lowers Inflammation : NF-kB↓, COX2↓, Pro-Inflammatory Cytokines : IL-1β↓, TNF-α↓, IL-6↓, IL-8↓
- inhibit Growth/Metastases : TumMeta↓, TumCG↓, EMT↓, MMPs↓, MMP2↓, MMP9↓, IGF-1↓, VEGF↓, FAK↓, NF-κB↓, TGF-β↓, α-SMA↓, ERK↓
- cause Cell cycle arrest : TumCCA↑, cyclin D1↓,
- inhibits Migration/Invasion : TumCMig↓, TumCI↓, TNF-α↓, FAK↓, ERK↓, EMT↓,
- inhibits glycolysis and ATP depletion : HIF-1α↓, PKM2↓, GLUT1↓, LDHA↓, HK2↓, PFKs↓, PDKs↓, ECAR↓, OXPHOS↓, GRP78↑, Glucose↓, GlucoseCon↓
- inhibits angiogenesis↓ : VEGF↓, HIF-1α↓, EGFR↓, Integrins↓,
- small indication of inhibiting Cancer Stem Cells : CSC↓, CD24↓, β-catenin↓,
- Others: PI3K↓, AKT↓, JAK↓, STAT↓, β-catenin↓, AMPK, ERK↓, JNK,
- Synergies: chemo-sensitization, chemoProtective, RadioSensitizer, RadioProtective, Others(review target notes), Neuroprotective, Cognitive, Renoprotection, Hepatoprotective, CardioProtective,

- Selectivity: Cancer Cells vs Normal Cells

Lipoic Acid Cancer Mechanisms

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Mitochondrial redox and ROS ↑ mitochondrial ROS; ↔/↓ total ROS (context-dependent) ↓ ROS P/R Apoptosis and redox disruption Central but bidirectional mechanism. HT-29 and A549 models show pro-oxidant ROS-mediated death, whereas MCF-7 and some prostate models show ROS lowering with growth inhibition.
2 PI3K Akt survival signaling ↓ Akt; ↑ p27; ↓ proliferation ↔/↑ Akt (context-dependent) R/G Cell-cycle arrest and apoptosis Breast cancer studies demonstrate suppression of Akt with G1 arrest, Bax/Bcl-2 shift and apoptotic signaling.
3 Mitochondria and MPTP ↑ permeability transition; ↓ membrane potential; ↑ cytochrome c Generally protected from oxidative mitochondrial injury R Intrinsic apoptosis Provides a mechanistic bridge between altered mitochondrial metabolism, ROS production and caspase activation.
4 ER stress CHOP XBP1 ↑ GRP78; ↑ CHOP; ↑ XBP1; ↑ caspases Not established as a therapeutic effect R/G ER-stress-mediated apoptosis Demonstrated prominently in A549 lung cancer cells and substantially dependent on ROS.
5 Ca²⁺ and TRPV1 signaling ↑ Ca²⁺; ↑ TRPV1-dependent mitochondrial apoptosis Context-dependent P/R Apoptotic amplification Particularly evident with cisplatin; Ca²⁺ has also been implicated in ALA-induced lung-cancer apoptosis.
6 Bax Bcl-2 caspase axis ↑ Bax; ↓ Bcl-2/Bcl-XL; ↑ caspase-3/9; ↑ PARP cleavage Often ↓ inappropriate apoptosis during oxidative injury R/G Apoptosis Downstream convergence point for multiple ALA-responsive pathways.
7 KEAP1 NRF2 p62 ↓ NRF2/p62 in selected prostate models ↑ NRF2; ↑ HO-1/SOD antioxidant defense R/G Context-dependent redox regulation NRF2 should not be classified simply as increased or decreased. ALA activates protective NRF2 signaling in normal cells but can suppress NRF2 in some malignant cells.
8 Glutathione redox system ↑ GSH in some models; ↓ functional antioxidant defense during pro-oxidant killing (context-dependent) ↑ GSH; ↑ GSH/GSSG ratio; ↑ antioxidant protection R/G Redox buffering and context-dependent modulation of apoptosis ALA/DHLA can increase intracellular GSH and stimulate GSH synthesis, particularly in normal or oxidatively stressed cells. In cancer cells, however, increased GSH can oppose ROS-dependent ALA cytotoxicity; several anticancer models instead show ROS accumulation or suppression of antioxidant enzymes. Therefore GSH is mechanistically important but not uniformly anticancer.
9 Autophagy mTOR Beclin-1 LC3 ↓ Beclin-1; ↓ LC3; ↓ autophagy in prostate models Context-dependent G Reduced cancer-cell survival ALA-associated ↑ mTOR and inhibition of autophagy have been reported in LNCaP and DU-145 cells; not established as universal.
10 NF-κB IKK inflammatory signaling ↓ NF-κB (model-dependent) ↓ inflammatory NF-κB activation R/G Reduced survival and inflammatory signaling ALA can inhibit IKK/NF-κB independently of its antioxidant activity, but much of the evidence is from non-malignant experimental systems.
11 Integrin FAK EMT invasion ↓ β1-integrin/FAK; ↓ MMP-2/MMP-9; ↓ EMT Not established G Reduced migration and invasion Preclinical evidence supports antimetastatic effects, but systemic clinical relevance has not been established.
12 Chemosensitization ↑ cisplatin-associated ROS, Ca²⁺ and apoptosis (model-dependent) ↓ chemotherapy-associated oxidative injury in several normal tissues R/G Potential selective treatment modulation ALA can enhance cisplatin cytotoxicity in cultured cancer cells while protecting normal tissue in other models. Clinical net effect on antitumor efficacy is unresolved.
13 Radiosensitivity and radioprotection ↔ antitumor radiosensitization not established ↓ radiation-induced ROS and tissue injury R/G Predominantly radioprotection Human and preclinical literature is oriented toward mitigation of normal-tissue radiation toxicity rather than tumor radiosensitization.
14 Clinical Translation Constraint Common experimental concentrations exceed oral systemic exposure Systemic antioxidant effects occur at clinically used doses G Limits direct anticancer translation Oral bioavailability is approximately 30%, elimination is rapid, and many cancer experiments use 250–1000 µM compared with transient human plasma concentrations typically in the low tens of micromolar.

P: 0–30 min    R: 30 min–3 hr    G: >3 hr

Lipoic acid and Alzheimer’s disease — ALA has sufficient AD-specific mechanistic and human evidence to justify a separate database section, although efficacy remains unproven. Its rationale includes mitochondrial cofactor activity, reduction of oxidative stress, regeneration of endogenous antioxidants, modulation of inflammatory signaling and potential improvement of neuronal glucose/energy metabolism. Small open-label studies using 600 mg/day reported slower cognitive decline, while a small randomized trial of omega-3 plus 600 mg/day ALA found less decline in selected MMSE and instrumental-ADL outcomes but no benefit in its primary oxidative-stress endpoint or ADAS-cog. Another randomized antioxidant combination containing 900 mg/day ALA produced an unexpected greater MMSE decline, making the clinical evidence mixed and insufficient for therapeutic conclusions.

Clinical evidence status: Small human / pilot RCT / adjunct use. No adequately powered confirmatory trial establishes ALA as a disease-modifying treatment for Alzheimer’s disease.

Lipoic Acid in Alzheimer’s Disease

Rank Pathway / Axis Modulation Primary Effect Notes / Interpretation
1 Oxidative stress and glutathione redox cycling ↓ ROS; ↑ antioxidant capacity Neuroprotection ALA/DHLA can scavenge oxidants and regenerate endogenous antioxidant systems; biologically plausible but clinical disease modification is unproven.
2 Mitochondrial energy metabolism ↑ mitochondrial cofactor function Support of neuronal bioenergetics Lipoyl groups are essential cofactors for pyruvate and α-ketoglutarate dehydrogenase complexes.
3 NRF2 antioxidant response ↑ NRF2-associated antioxidant defense Reduced oxidative injury Well supported mechanistically in non-cancer tissues but direct AD clinical validation is limited.
4 NF-κB inflammatory signaling ↓ NF-κB Reduced neuroinflammatory signaling Mechanistically plausible; much supporting evidence is indirect rather than from human AD brain studies.
5 Cognitive and functional decline ↔/↓ decline (study-dependent) Possible clinical neuroprotection Small open-label and omega-3 plus ALA studies produced signals of benefit, but larger confirmatory evidence is lacking and antioxidant-combination data include a possible adverse cognitive signal.


Scientific Papers found: Click to Expand⟱
279- ALA,    Lipoic acid-induced oxidative stress abrogates IGF-1R maturation by inhibiting the CREB/furin axis in breast cancer cell lines
- in-vitro, BC, MCF7 - in-vitro, BC, MDA-MB-231
Furin↓, IGF-1R↓, ROS↑, CREB↓, Furin↓, IGF-1R↓,
278- ALA,    The Multifaceted Role of Alpha-Lipoic Acid in Cancer Prevention, Occurrence, and Treatment
- Review, Var, NA
ROS↑, NRF2↑, Inflam↓, frataxin↑, *BioAv↓, ChemoSen↑, Hif1a↓, Synergy↑, FAK↓, ITGB1↓, MMP2↓, MMP9↓, EMT↓, Snail↓, Vim↓, Zeb1↓, P53↑, MGMT↓, Mcl-1↓, Bcl-xL↓, Bcl-2↓, survivin↓, Casp3↑, Casp9↑, BAX↑, p‑Akt↓, GSK‐3β↓, *antiOx↑, *ROS↓, selectivity↑, angioG↓, MMPs↓, NF-kB↓, ITGB3↓, NADPH↓,
277- ALA,    α-lipoic acid modulates prostate cancer cell growth and bone cell differentiation
- in-vitro, Pca, 22Rv1 - in-vitro, Pca, C4-2B
ROS↑, Hif1a↑, JNK↑, Casp3↑, P21↑, BAX↑, Bcl-xL↓, cFos↓,
276- ALA,    Alpha lipoic acid diminishes migration and invasion in hepatocellular carcinoma cells through an AMPK-p53 axis
- in-vitro, HCC, HepG2 - in-vitro, HCC, Hep3B
P53↑, EMT↓, AMPK↑, cycD1/CCND1↓, TumCMig↓,
274- ALA,  LDN,    Revisiting the ALA/N (alpha-lipoic acid/low-dose naltrexone) protocol for people with metastatic and nonmetastatic pancreatic cancer: a report of 3 new cases
- Human, PC, NA
OS↑,
285- ALA,  HCA,    Tolerance of oral lipoid acid and hydroxycitrate combination in cancer patients: first approach of the cancer metabolism research group
- Human, Var, NA
PI3K↝, AMPK↝, TumCG↓, *toxicity↓, Weight∅,
271- ALA,  VitC,  LDN,    The Long-Term Survival of a Patient With Stage IV Renal Cell Carcinoma Following an Integrative Treatment Approach Including the Intravenous α-Lipoic Acid/Low-Dose Naltrexone Protocol
- Case Report, RCC, NA
OS↑, Weight↑, TumVol↓,
267- ALA,    α-Lipoic Acid Targeting PDK1/NRF2 Axis Contributes to the Apoptosis Effect of Lung Cancer Cells
- vitro+vivo, Lung, A549 - vitro+vivo, Lung, PC9
Apoptosis↑, ROS↑, PDK1 / PDPK1↓, NRF2↓, PDK1 / PDPK1↓, Bcl-2↓, Casp9↑, Dose∅,
266- ALA,    Lipoic acid decreases Mcl-1, Bcl-xL and up regulates Bim on ovarian carcinoma cells leading to cell death
- in-vitro, Ovarian, IGROV1
Mcl-1↓, Bcl-xL↓, BIM↑, ROS↑,
265- ALA,    Alpha-Lipoic Acid Reduces Cell Growth, Inhibits Autophagy, and Counteracts Prostate Cancer Cell Migration and Invasion: Evidence from In Vitro Studies
- in-vitro, Pca, LNCaP - in-vitro, Pca, DU145
ROS↓, SOD↓, GSTP1/GSTπ↓, NRF2↓, p62↓, p62↑, SOD↑, p‑mTOR↑, Beclin-1/ATG6↓, ROS↑, SOD1↑,
264- ALA,    α-Lipoic acid induces Endoplasmic Reticulum stress-mediated apoptosis in hepatoma cells
- in-vitro, HCC, FaO
ROS↑, P53↑, ER Stress↑, UPR↑, CHOP/DDIT3↑, PDI↑, GRP78/BiP↑, GRP58↓,
263- ALA,    Alpha-lipoic acid induces p27Kip-dependent cell cycle arrest in non-transformed cell lines and apoptosis in tumor cell lines
- in-vitro, SCC, Jurkat - in-vitro, SCC, FaDu
p27/CDKN1B↑,
262- ALA,    Lipoic acid decreases breast cancer cell proliferation by inhibiting IGF-1R via furin downregulation
- in-vitro, BC, MCF7 - in-vitro, BC, MDA-MB-231
TumCP↓, Akt↓, ERK↓, IGF-1R↓, Furin↓, Ki-67↓, AMPK↑, mTOR↓,
261- ALA,    The natural antioxidant alpha-lipoic acid induces p27(Kip1)-dependent cell cycle arrest and apoptosis in MCF-7 human breast cancer cells
- in-vitro, BC, MCF7
ROS↓, Akt↓, p27/CDKN1B↑, Bax:Bcl2↑,
260- ALA,    The effects of alpha-lipoic acid on breast of female albino rats exposed to malathion: Histopathological and immunohistochemical study
- in-vivo, BC, NA
PCNA↓, P53↓, Apoptosis↑, BAX↑,
258- ALA,    Effects of α-lipoic acid on cell proliferation and apoptosis in MDA-MB-231 human breast cells
- in-vitro, BC, MDA-MB-231
TumCG↓, p‑Akt↓, Akt↓, HER2/EBBR2↓, Bcl-2↓, BAX↑, Casp3↑,
296- ALA,    Lipoic acid inhibits cell proliferation of tumor cells in vitro and in vivo
- vitro+vivo, neuroblastoma, SK-N-SH - vitro+vivo, BC, SkBr3
TumCG↓, Casp3↑,
304- ALA,    alpha-Lipoic acid induces apoptosis in human colon cancer cells by increasing mitochondrial respiration with a concomitant O2-*-generation
- in-vitro, Colon, HT-29
mt-ROS↑, Apoptosis↑, Casp3↑, DNAdam↑, Bcl-xL↓, Dose↝,
303- ALA,  LDN,    The long-term survival of a patient with pancreatic cancer with metastases to the liver after treatment with the intravenous alpha-lipoic acid/low-dose naltrexone protocol
- Case Report, PC, NA
OS↑,
302- ALA,    The Antioxidant Alpha-Lipoic Acid Inhibits Proliferation and Invasion of Human Gastric Cancer Cells via Suppression of STAT3-Mediated MUC4 Gene Expression
- in-vitro, GC, AGS - in-vitro, GC, BGC-823 - in-vitro, GC, MKN-28
MUC4↓, STAT3↓,
301- ALA,  PacT,  doxoR,    Role of alpha-lipoic acid in counteracting paclitaxel- and doxorubicin-induced toxicities: a randomized controlled trial in breast cancer patients
- Human, BC, NA
BNP↓, TNF-α↓, MDA↓, NeuroT↓,
1124- ALA,    Alpha lipoic acid inhibits proliferation and epithelial mesenchymal transition of thyroid cancer cells
- in-vitro, Thyroid, BCPAP - in-vitro, Thyroid, HTH-83 - in-vitro, Thyroid, CAL-62 - in-vitro, Thyroid, FTC-133 - in-vivo, NA, NA
TumCP↓, AMPK↑, mTOR↓, TumCMig↓, TumCI↓, EMT↓, E-cadherin↑, β-catenin/ZEB1↓, Vim↓, Snail↓, Twist↓, TGF-β↓, p‑SMAD2↓, TumCG↓,
299- ALA,  Cisplatin,  PacT,    Anti-cancer effects of alpha lipoic acid, cisplatin and paclitaxel combination in the OVCAR-3 ovarian adenocarcinoma cell line
- in-vitro, Ovarian, OVCAR-3
MMP9↓, MMP11↓, MAPK↓,
298- ALA,  Rad,    Synergistic Tumoricidal Effects of Alpha-Lipoic Acid and Radiotherapy on Human Breast Cancer Cells via HMGB1
- in-vitro, BC, MDA-MB-231
Apoptosis↑, P53↑, p38↑, NF-kB↑, TumCCA↑,
297- ALA,    Insights on the Use of α-Lipoic Acid for Therapeutic Purposes
- Review, BC, SkBr3 - Review, neuroblastoma, SK-N-SH - Review, AD, NA
PDH↑, TumCG↓, ROS↑, AMPK↑, EGR4↓, Half-Life↓, BioAv↝, *GSH↑, *IronCh↑, *ROS↓, *antiOx↑, *neuroP↑, *Ach↑, *lipid-P↓, *IL1β↓, *IL6↓, TumCP↓, FDG↓, Apoptosis↑, AMPK↑, mTOR↓, EGFR↓, TumCI↓, TumCMig↓, *memory↑, *BioAv↑, *BioAv↝, *other↓, *other↝, *Half-Life↓, *BioAv↑, *ChAT↑, *GlucoseCon↑,
295- ALA,    α-Lipoic acid suppresses migration and invasion via downregulation of cell surface β1-integrin expression in bladder cancer cells
- in-vitro, Bladder, T24/HTB-9
ITGB1↓, TumCMig↓, ERK↓, Akt↓,
291- ALA,  HCA,  MET,  DFC,    Metabolic therapies inhibit tumor growth in vivo and in silico
- in-vivo, Melanoma, B16-F10 - in-vivo, Lung, LL/2 (LLC1) - in-vivo, Bladder, MBT-2
TumCG↓,
290- ALA,  HCA,    A combination of alpha lipoic acid and calcium hydroxycitrate is efficient against mouse cancer models: preliminary results
- vitro+vivo, Melanoma, B16-F10
TumCG↓, OS↑,
289- ALA,  HCA,  EA,    Cancer Metabolism: Fasting Reset, the Keto-Paradox and Drugs for Undoing
- Analysis, Var, NA
ACLY↓,
288- ALA,  HCA,  CAP,  Octr,    Tumor regression with a combination of drugs interfering with the tumor metabolism: efficacy of hydroxycitrate, lipoic acid and capsaicin
- in-vivo, Var, NA
TumCG↓,
287- ALA,  HCA,  Lyco,    Metabolic treatment of cancer: intermediate results of a prospective case series
- Case Report, Var, NA
PSA↓, OS↑,
1235- ALA,  Cisplatin,    α-Lipoic acid prevents against cisplatin cytotoxicity via activation of the NRF2/HO-1 antioxidant pathway
- in-vitro, Nor, HEI-OC1 - ex-vivo, NA, NA
ROS↑, HO-1↓, *toxicity↓, chemoP↑, *ROS↓, *HO-1↑, *SOD1↑, *NRF2↑,
286- HCA,  ALA,    Adding a combination of hydroxycitrate and lipoic acid (METABLOC™) to chemotherapy improves effectiveness against tumor development: experimental results and case report
- Case Report, Var, NA
OS↑,
1628- HCA,  ALA,    Addition of Hydroxy Citrate improves effect of ALA
- Review, Var, NA
ACLY↓, other↓, ROS↑, Synergy↑, PDKs↓,
1255- PI,  ALA,    Antileukemic effects of piperlongumine and alpha lipoic acid combination on Jurkat, MEC1 and NB4 cells in vitro
- in-vitro, CLL, NA
COX2/PTGS2↓, Casp3↑,
609- VitC,  ALA,  VitK3,  Se,    Vitamin C and Cancer: Is There A Use For Oral Vitamin C?
- Review, Var, NA
OS↑,
300- VitC,  ALA,    Combination of High-Dose Parenteral Ascorbate (Vitamin C) and Alpha-Lipoic Acid Failed to Enhance Tumor-Inhibitory Effect But Increased Toxicity in Preclinical Cancer Models
- in-vitro, BC, MDA-MB-231 - in-vitro, Colon, HCT116 - in-vitro, Ovarian, PANC1 - in-vitro, Pca, PC3
TumCG∅,

Showing Research Papers: 51 to 87 of 87
Prev Page 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 87

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

frataxin↑, 1,   H2O2↑, 1,   HO-1↓, 1,   lipid-P↑, 1,   MDA↓, 1,   NRF2↓, 2,   NRF2↑, 1,   ROS↓, 3,   ROS↑, 18,   mt-ROS↑, 2,   SOD↓, 1,   SOD↑, 1,   SOD1↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

mitResp↓, 1,   mtDam↑, 1,   OCR↓, 1,   OXPHOS↓, 1,   PDH↑, 2,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ACLY↓, 2,   AMPK↑, 5,   AMPK↝, 1,   p‑AMPK↑, 1,   ATP↓, 3,   ECAR↓, 1,   FDG↓, 1,   GlucoseCon↓, 3,   Glycolysis↓, 4,   GSK‐3β↓, 1,   HK2↓, 1,   lactateProd↓, 1,   LDHA↓, 2,   NAD↓, 1,   NADPH↓, 1,   PDK1 / PDPK1↓, 2,   PDKs↓, 1,   PFK↓, 1,   PKM2↓, 2,  

Cell Death(tgid=5) ⓘ

Apoptosis↑, 8,   BAX↑, 5,   Bax:Bcl2↑, 1,   Bcl-2↓, 4,   Bcl-xL↓, 4,   BIM↑, 1,   Casp↑, 3,   Casp3↑, 7,   Casp9↑, 4,   Cyt‑c↑, 1,   GRP58↓, 1,   Mcl-1↓, 2,   p38↑, 1,   survivin↓, 2,  

Kinase & Signal Transduction(tgid=6) ⓘ

Akt↓, 7,   p‑Akt↓, 3,   CREB↓, 1,   EGFR↓, 2,   ERK↓, 2,   HER2/EBBR2↓, 1,   IGF-1R↓, 4,   IKKα↓, 1,   JNK↑, 3,   MAPK↓, 1,   mTOR↓, 5,   p‑mTOR↑, 2,   p‑P70S6K↓, 1,   p‑P70S6K↑, 1,   PI3K↓, 2,   PI3K↝, 1,   STAT3↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

other↓, 1,   other↝, 1,   tumCV↓, 2,  

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP/DDIT3↑, 1,   ER Stress↑, 1,   GRP78/BiP↑, 1,   PDI↑, 1,   UPR↑, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

Beclin-1/ATG6↓, 1,   LC3B-II↑, 1,   p62↓, 1,   p62↑, 1,   TumAuto↓, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↑, 1,   MGMT↓, 1,   P53↓, 1,   P53↑, 4,   p‑P53↑, 1,   PARP1↑, 1,   PCNA↓, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

Cyc↓, 1,   cycD1/CCND1↓, 1,   Ki-67↓, 1,   P21↑, 2,   p27/CDKN1B↑, 3,   TumCCA↑, 3,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

ALDH↓, 1,   CD24↓, 1,   cFos↓, 1,   CSCs↓, 2,   Ki-67↓, 1,   TumCG↓, 9,   TumCG↑, 1,   TumCG∅, 1,   TumCP↓, 3,  

Migration(tgid=13) ⓘ

E-cadherin↑, 1,   EMT↓, 4,   FAK↓, 1,   Furin↓, 4,   ITGB1↓, 2,   ITGB3↓, 1,   MMP11↓, 1,   MMP2↓, 2,   MMP9↓, 4,   MMPs↓, 1,   MUC4↓, 1,   NeuroT↓, 1,   p‑SMAD2↓, 1,   Snail↓, 2,   TGF-β↓, 1,   TumCI↓, 3,   TumCMig↓, 5,   TumMeta↓, 2,   Twist↓, 1,   Vim↓, 2,   Zeb1↓, 1,   β-catenin/ZEB1↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 2,   EGR4↓, 1,   Hif1a↓, 1,   Hif1a↑, 2,  

Barriers & Transport(tgid=15) ⓘ

MMP↓, 3,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

CD44↓, 1,   COX2/PTGS2↓, 1,   Inflam↓, 1,   NF-kB↓, 2,   NF-kB↑, 1,   PSA↓, 1,   TNF-α↓, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

BNP↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↝, 1,   ChemoSen↑, 4,   Dose↑, 1,   Dose↝, 1,   Dose∅, 2,   eff↓, 2,   eff↑, 1,   GSTP1/GSTπ↓, 1,   Half-Life↓, 1,   RadioS↑, 1,   selectivity↑, 4,   Synergy↑, 2,  

Clinical Biomarkers(tgid=22) ⓘ

EGFR↓, 2,   HER2/EBBR2↓, 1,   PSA↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 1,   chemoP↑, 1,   cognitive?, 1,   neuroP↑, 1,   OS↑, 7,   RenoP↑, 1,   TumVol↓, 1,   Weight↑, 1,   Weight∅, 1,  
Total Targets: 162

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 25,   Catalase↑, 4,   GPx↑, 5,   GSH↑, 19,   GSR↑, 1,   GSSG↓, 1,   GSTs↑, 1,   H2O2↓, 1,   H2O2∅, 1,   HO-1↑, 5,   Iron↓, 1,   lipid-P↓, 9,   MDA↓, 3,   NOX4↓, 1,   NQO1↑, 3,   NRF2↑, 10,   ROS↓, 26,   ROS↑, 1,   SOD↑, 4,   SOD1↑, 1,   TAC↑, 1,   VitC↑, 4,   VitE↑, 4,  

Metal & Cofactor Biology(tgid=2) ⓘ

IronCh↑, 17,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

PDH↑, 1,   PGC-1α↑, 1,   SIRT3↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ACC↑, 1,   Acetyl-CoA↑, 3,   adiP↑, 2,   ALAT↓, 1,   AMPK↑, 2,   AMPK⇅, 1,   ATP↑, 2,   cAMP↑, 2,   DHA↑, 1,   FAO↑, 1,   glucose↑, 1,   GlucoseCon↑, 11,   Glycolysis↑, 1,   HK1↑, 1,   NADPH↑, 1,   PDKs↓, 1,   SIRT1↑, 2,  

Cell Death(tgid=5) ⓘ

Apoptosis↓, 2,   Casp3↓, 2,   Casp6↓, 1,   Casp9↓, 3,   iNOS↓, 4,   p38↑, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

Akt?, 1,   Akt↑, 3,   ERK↑, 3,   JAK↓, 1,   JNK↓, 1,   MAPK↓, 1,   MAPK↑, 2,   PI3K↑, 3,   PKCδ↑, 2,   PTEN↓, 2,   STAT↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

cMyc↓, 1,   FOXO1↑, 1,   FOXO3↑, 1,   other?, 1,   other↓, 1,   other↑, 2,   other↝, 4,  

DNA Damage & Repair(tgid=10) ⓘ

ATM↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

CD34↑, 1,   IGF-1↑, 1,  

Migration(tgid=13) ⓘ

Ca+2↓, 1,   COL3A1↓, 1,   MMP9↓, 2,   α-SMA↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

E-sel↓, 1,   eNOS↓, 1,   eNOS↑, 1,   Hif1a↑, 3,   NO↓, 3,   VCAM-1↓, 7,   VEGF↓, 1,   VEGF↑, 2,  

Barriers & Transport(tgid=15) ⓘ

BBB↑, 13,   GLUT1↑, 1,   GLUT3↑, 3,   GLUT4↑, 5,   MMP↑, 2,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↓, 2,   ICAM-1↓, 3,   IL1β↓, 6,   IL2↓, 1,   IL6↓, 5,   IL8↓, 1,   INF-γ↓, 1,   Inflam↓, 17,   MCP1/CCL2↓, 1,   NF-kB↓, 12,   p‑NF-kB↓, 1,   PGE2↓, 1,   TNF-α↓, 6,  

Synaptic & Neurotransmission(tgid=18) ⓘ

5HT↑, 2,   Ach↑, 7,   AChE↓, 2,   BDNF↑, 1,   ChAT↑, 7,  

Protein Aggregation(tgid=19) ⓘ

Aβ↓, 7,   tau↓, 1,   p‑tau↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 3,   BioAv↑, 5,   BioAv↝, 7,   Dose↝, 1,   eff↓, 1,   eff↑, 3,   Half-Life↓, 4,   Synergy↑, 2,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 1,   ALP↓, 1,   AST↓, 1,   BG↓, 1,   BP↓, 1,   BP↝, 1,   BUN↓, 1,   creat↓, 1,   IL6↓, 5,   LDH↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiAge↑, 3,   AntiCan↑, 1,   cardioP?, 1,   cardioP↓, 1,   cardioP↑, 3,   chemoP↑, 1,   cognitive↑, 17,   cognitive∅, 2,   hepatoP↑, 2,   memory↑, 10,   motorD↑, 3,   neuroP↑, 19,   radioP↑, 1,   RenoP↑, 1,   toxicity↓, 3,   toxicity∅, 1,   Weight↓, 1,  

Infection & Microbiome(tgid=24) ⓘ

GutMicro↑, 1,   Sepsis↓, 1,  
Total Targets: 146

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:29  Target#:%  State#:%  Dir#:%
wNotes=0 sortOrder:rid,rpid

 

Home Page